drugset / Trial / NCT06553768
Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine whether the investigational treatment (maralixibat) is safe and effective in pediatric and adult participants who have cholestatic liver disease with pruritus that has been refractory to other therapies, and who have no other treatment options.
Timeline
- Start
- 2024-10-14
- Primary completion
- 2026-10
- Completion
- 2027-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Maralixibat | Small molecule | 300 ug/kg | Oral |
Indications
No indication recorded.